(STVN) Stevanato SpA - Overview
Stock: Syringes, Vials, Cartridges, Injectors, Inspection Machines
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.27% |
| Yield on Cost 5y | 0.32% |
| Yield CAGR 5y | 4.71% |
| Payout Consistency | 99.0% |
| Payout Ratio | 17.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 53.2% |
| Relative Tail Risk | -3.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.55 |
| Alpha | -42.66 |
| Character TTM | |
|---|---|
| Beta | 0.818 |
| Beta Downside | 0.398 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.90% |
| CAGR/Max DD | -0.13 |
Description: STVN Stevanato SpA January 09, 2026
Stevanato Group S.p.A. (NYSE: STVN) designs, manufactures, and distributes a broad portfolio of drug-containment and diagnostic solutions-including pre-fillable syringes, cartridges, vials, ampoules, pen and auto-injectors, wearable injectors, laboratory consumables, visual-inspection systems, and glass-forming equipment-serving biopharma, biotech, diagnostics, and life-science customers worldwide across two operating segments: Biopharmaceutical & Diagnostic Solutions and Engineering.
Key operational metrics that have recently drawn analyst attention are a 12% YoY increase in contract manufacturing revenue (driven by rising demand for ready-to-use injectable devices) and a 7% expansion in the diagnostic consumables segment, reflecting growth in point-of-care testing. The company’s exposure to the global shift toward biologics and personalized medicine positions it to benefit from higher volumes of sterile packaging and advanced delivery devices, while its European-centric supply chain offers cost-advantageous proximity to major pharma hubs.
Given the accelerating adoption of single-use bioprocessing and the projected CAGR of ~6% for the global drug-delivery device market through 2030, Stevanato’s integrated glass-forming and filling capabilities could provide a defensible competitive moat.
For a deeper, data-driven view of how Stevanato’s fundamentals stack up against sector peers, you may find ValueRay’s analytical dashboard worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 140.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 10.56 > 1.0 |
| NWC/Revenue: 35.63% < 20% (prev 35.32%; Δ 0.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 235.6m > Net Income 140.6m |
| Net Debt (337.0m) to EBITDA (279.5m): 1.21 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (273.0m) vs 12m ago 0.04% < -2% |
| Gross Margin: 28.63% > 18% (prev 0.28%; Δ 2835 % > 0.5%) |
| Asset Turnover: 50.58% > 50% (prev 49.42%; Δ 1.16% > 0%) |
| Interest Coverage Ratio: 24.91 > 6 (EBITDA TTM 279.5m / Interest Expense TTM 7.86m) |
Altman Z'' 4.31
| A: 0.17 (Total Current Assets 884.5m - Total Current Liabilities 467.4m) / Total Assets 2.41b |
| B: 0.36 (Retained Earnings 863.4m / Total Assets 2.41b) |
| C: 0.08 (EBIT TTM 195.9m / Avg Total Assets 2.31b) |
| D: 1.38 (Book Value of Equity 1.34b / Total Liabilities 976.9m) |
| Altman-Z'' Score: 4.31 = AA |
Beneish M -2.43
| DSRI: 1.71 (Receivables 489.9m/268.1m, Revenue 1.17b/1.09b) |
| GMI: 0.98 (GM 28.63% / 27.97%) |
| AQI: 1.04 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.07 (Revenue 1.17b / 1.09b) |
| TATA: -0.04 (NI 140.6m - CFO 235.6m) / TA 2.41b) |
| Beneish M-Score: -2.43 (Cap -4..+1) = BBB |
What is the price of STVN shares?
Over the past week, the price has changed by -0.51%, over one month by -28.21%, over three months by -36.50% and over the past year by -30.86%.
Is STVN a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the STVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.7 | 85% |
| Analysts Target Price | 28.7 | 85% |
| ValueRay Target Price | 13.7 | -11.7% |
STVN Fundamental Data Overview February 03, 2026
P/E Trailing = 25.9667
P/E Forward = 20.2429
P/S = 3.6342
P/B = 2.5292
P/EG = 3.5691
Revenue TTM = 1.17b EUR
EBIT TTM = 195.9m EUR
EBITDA TTM = 279.5m EUR
Long Term Debt = 358.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 82.9m EUR (from shortTermDebt, last quarter)
Debt = 450.3m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 337.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.94b EUR (3.60b + Debt 450.3m - CCE 113.3m)
Interest Coverage Ratio = 24.91 (Ebit TTM 195.9m / Interest Expense TTM 7.86m)
EV/FCF = -116.8x (Enterprise Value 3.94b / FCF TTM -33.7m)
FCF Yield = -0.86% (FCF TTM -33.7m / Enterprise Value 3.94b)
FCF Margin = -2.88% (FCF TTM -33.7m / Revenue TTM 1.17b)
Net Margin = 12.01% (Net Income TTM 140.6m / Revenue TTM 1.17b)
Gross Margin = 28.63% ((Revenue TTM 1.17b - Cost of Revenue TTM 835.3m) / Revenue TTM)
Gross Margin QoQ = 29.19% (prev 28.06%)
Tobins Q-Ratio = 1.63 (Enterprise Value 3.94b / Total Assets 2.41b)
Interest Expense / Debt = 0.39% (Interest Expense 1.77m / Debt 450.3m)
Taxrate = 26.59% (13.1m / 49.1m)
NOPAT = 143.8m (EBIT 195.9m * (1 - 26.59%))
Current Ratio = 1.89 (Total Current Assets 884.5m / Total Current Liabilities 467.4m)
Debt / Equity = 0.31 (Debt 450.3m / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = 1.21 (Net Debt 337.0m / EBITDA 279.5m)
Debt / FCF = -9.99 (negative FCF - burning cash) (Net Debt 337.0m / FCF TTM -33.7m)
Total Stockholder Equity = 1.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.08% (Net Income 140.6m / Total Assets 2.41b)
RoE = 9.94% (Net Income TTM 140.6m / Total Stockholder Equity 1.41b)
RoCE = 11.05% (EBIT 195.9m / Capital Employed (Equity 1.41b + L.T.Debt 358.0m))
RoIC = 7.90% (NOPAT 143.8m / Invested Capital 1.82b)
WACC = 7.97% (E(3.60b)/V(4.05b) * Re(8.93%) + D(450.3m)/V(4.05b) * Rd(0.39%) * (1-Tc(0.27)))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.40%
Fair Price DCF = unknown (Cash Flow -33.7m)
EPS Correlation: -35.21 | EPS CAGR: -46.67% | SUE: -4.0 | # QB: 0
Revenue Correlation: 63.64 | Revenue CAGR: 7.32% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.002 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=0.74 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+21.0% | Growth Revenue=+9.6%